This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
This commentary highlights limitations of traditional access metrics and proposes incorporating eConsults to better capture specialty capacity, workload, and performance in modern health care delivery.